Recombinant Activated Factor VII (rFVIIa) + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Dec 3, 2021 → Jan 1, 2028
NCT ID
NCT03496883About Recombinant Activated Factor VII (rFVIIa) + Placebo
Recombinant Activated Factor VII (rFVIIa) + Placebo is a phase 3 stage product being developed by Novo Nordisk for Intracerebral Hemorrhage. The current trial status is active. This product is registered under clinical trial identifier NCT03496883. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03496883 | Phase 3 | Active |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |
| Albumin + Placebo | Baxter | Phase 2 | 49 |